Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history.
LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...
On Monday, GSK plc (NYSE:GSK) released headline results ... nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52. Also Read: GSK’s Asthma ...
The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... growth by minus 8% this quarter, meaning underlying operating profit was ...
The update on the GSK-partnered prospect sent Wave’s share ... Circulating wild-type M-AAT protein in plasma reached a mean of 6.9 micromolar at day 15. At that time, the wild-type protein ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback